Automated QbD-Based Method Development and Validation of Oxidative Degraded Atorvastatin

Applications | 2014 | Agilent TechnologiesInstrumentation
HPLC
Industries
Pharma & Biopharma
Manufacturer
Agilent Technologies
Downloadable PDF for viewing
 

Similar PDF

Peptide Mapping: A Quality by Design (QbD) Approach
Peptide Mapping: A Quality by Design (QbD) Approach
2017|Agilent Technologies|Applications
Quality‑by‑Design Approach to Stability Indicating Method Development for Linagliptin Drug Product
QbD Based Method Development on an Agilent 1290 Infinity UHPLC System Combined with a Seamless Method Transfer to HPLC Using Intelligent System Emulation Technology
Regulations for Analytical development USFDA/ICH/USP perspectives